Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH).

The NASH study is a multi-center, double-blind, randomized, placebo-controlled study in patients with Non-alcoholic Steatohepatitis (NASH). The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven NASH.

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.


Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434